Teachers Advisors LLC boosted its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 1.4% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 756,186 shares of the biopharmaceutical company’s stock after buying an additional 10,261 shares during the quarter. Teachers Advisors LLC owned approximately 0.40% of Amicus Therapeutics worth $9,142,000 at the end of the most recent quarter.
Other large investors have also bought and sold shares of the company. Neuberger Berman Group LLC raised its holdings in Amicus Therapeutics by 44.4% during the third quarter. Neuberger Berman Group LLC now owns 130,000 shares of the biopharmaceutical company’s stock worth $1,572,000 after purchasing an additional 40,000 shares in the last quarter. MetLife Investment Advisors LLC raised its holdings in Amicus Therapeutics by 55.5% during the third quarter. MetLife Investment Advisors LLC now owns 133,286 shares of the biopharmaceutical company’s stock worth $1,611,000 after purchasing an additional 47,562 shares in the last quarter. Putnam Investments LLC raised its holdings in Amicus Therapeutics by 144.5% during the third quarter. Putnam Investments LLC now owns 207,492 shares of the biopharmaceutical company’s stock worth $2,508,000 after purchasing an additional 122,614 shares in the last quarter. Point72 Asset Management L.P. raised its holdings in Amicus Therapeutics by 229.3% during the third quarter. Point72 Asset Management L.P. now owns 2,329,200 shares of the biopharmaceutical company’s stock worth $28,160,000 after purchasing an additional 1,621,900 shares in the last quarter. Finally, Sofinnova Ventures Inc purchased a new position in Amicus Therapeutics during the third quarter worth about $5,392,000.
Shares of Amicus Therapeutics stock opened at $11.74 on Friday. Amicus Therapeutics, Inc. has a 12-month low of $8.27 and a 12-month high of $17.62. The company has a debt-to-equity ratio of 0.78, a current ratio of 9.12 and a quick ratio of 9.03. The stock has a market capitalization of $2.17 billion, a price-to-earnings ratio of -4.02 and a beta of 1.52.
Amicus Therapeutics (NASDAQ:FOLD) last issued its earnings results on Monday, November 5th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.27) by ($0.04). Amicus Therapeutics had a negative net margin of 463.82% and a negative return on equity of 52.03%. The company had revenue of $20.60 million during the quarter, compared to analysts’ expectations of $23.56 million. During the same period last year, the business posted ($0.41) earnings per share. The company’s quarterly revenue was up 89.0% on a year-over-year basis. As a group, sell-side analysts predict that Amicus Therapeutics, Inc. will post -1.22 earnings per share for the current year.
In other Amicus Therapeutics news, CFO William D. Baird III sold 10,000 shares of the stock in a transaction dated Monday, October 15th. The shares were sold at an average price of $12.23, for a total value of $122,300.00. Following the completion of the transaction, the chief financial officer now directly owns 127,622 shares of the company’s stock, valued at $1,560,817.06. The sale was disclosed in a filing with the SEC, which is available at this link. Company insiders own 2.90% of the company’s stock.
Several research firms recently issued reports on FOLD. Zacks Investment Research cut shares of Amicus Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday. BidaskClub raised shares of Amicus Therapeutics from a “strong sell” rating to a “sell” rating in a report on Friday, January 4th. ValuEngine cut shares of Amicus Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Wednesday, January 2nd. Guggenheim began coverage on shares of Amicus Therapeutics in a report on Monday, December 17th. They set a “buy” rating and a $18.00 price target for the company. Finally, Citigroup began coverage on shares of Amicus Therapeutics in a report on Monday, October 29th. They set a “neutral” rating and a $12.00 price target for the company. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $19.29.
TRADEMARK VIOLATION WARNING: “Amicus Therapeutics, Inc. (FOLD) Position Boosted by Teachers Advisors LLC” was originally reported by Transcript Daily and is owned by of Transcript Daily. If you are viewing this piece of content on another publication, it was stolen and republished in violation of United States & international trademark & copyright legislation. The legal version of this piece of content can be read at https://transcriptdaily.com/2019/01/12/amicus-therapeutics-inc-fold-position-boosted-by-teachers-advisors-llc.html.
Amicus Therapeutics Company Profile
Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 to investigate in patients with pompe disease.
Featured Story: What is Compound Interest?
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.